Date post: | 29-May-2018 |
Category: |
Documents |
Upload: | buntyjagiwala |
View: | 231 times |
Download: | 0 times |
of 42
8/9/2019 Lyophilization Processes Jan 05
1/42
Lyophilization Processes:Lyophilization Processes:
A Compliance/EnforcementA Compliance/Enforcement
PerspectivePerspective
Anne Johnson, Compliance OfficerAnne Johnson, Compliance Officer
Office of Regulatory Affairs/Office of EnforcementOffice of Regulatory Affairs/Office of EnforcementDivision of Compliance Management and OperationsDivision of Compliance Management and Operations
DELAWARE VALLEY CHAPTER MEETING of the
INTERNATIONAL SOCIETY OF LYOPHILIZATION
PLYMOUTH MEETING, PA JANUARY 25, 2005
8/9/2019 Lyophilization Processes Jan 05
2/42
OBJECTIVESOBJECTIVES
Organizational Structure of FDA ComplianceOrganizational Structure of FDA Compliance
FDAs Regulatory Options/Enforcement PostureFDAs Regulatory Options/Enforcement Posture
Specific Examples of DeviationsSpecific Examples of Deviations
Written ResponsesWritten Responses
Dispute ResolutionDispute Resolution
8/9/2019 Lyophilization Processes Jan 05
3/42
8/9/2019 Lyophilization Processes Jan 05
4/42
OFFICE OF REGULATORYOFFICE OF REGULATORY
AFFAIRSAFFAIRS
8/9/2019 Lyophilization Processes Jan 05
5/42
FDA DISTRICTFDA DISTRICT
ORA DISTRICT INVESTIGATORORA DISTRICT INVESTIGATOR
ORA DISTRICT COMPLIANCE BRANCHORA DISTRICT COMPLIANCE BRANCH
APPROPRIATE CENTER FOR REVIEW ANDAPPROPRIATE CENTER FOR REVIEW ANDCONCURRENCE (CDER)CONCURRENCE (CDER)
OFFICE OF CHIEF COUNSELOFFICE OF CHIEF COUNSEL
ORA OFFICE OF ENFORCEMENT (HIGHERORA OFFICE OF ENFORCEMENT (HIGHERACTIONS SUCH AS INJUNCTIONS, ETC.)ACTIONS SUCH AS INJUNCTIONS, ETC.)
8/9/2019 Lyophilization Processes Jan 05
6/42
FDA DISTRICTSFDA DISTRICTS
LETTER ISSUED OR ACTION EXECUTEDLETTER ISSUED OR ACTION EXECUTED
BY ORA DISTRICT STAFFBY ORA DISTRICT STAFF
RESPONSES AND COMMUNICATIONSRESPONSES AND COMMUNICATIONS
COORDINATED WITH DISTRICT STAFFCOORDINATED WITH DISTRICT STAFF
8/9/2019 Lyophilization Processes Jan 05
7/42
TEAM BIOLOGICSTEAM BIOLOGICS -- InspectionsInspections
SPECIALIZED GROUP OF ORA INVESTIGATORSSPECIALIZED GROUP OF ORA INVESTIGATORSTHAT REPORT TO ORAs OFFICE OF REGIONALTHAT REPORT TO ORAs OFFICE OF REGIONALOPERATIONSOPERATIONS
PRODUCTS COVERED:PRODUCTS COVERED:
Vaccines, Allergenic Products, Plasma FractionatedVaccines, Allergenic Products, Plasma FractionatedProducts, In Vitro Diagnostic Products, andProducts, In Vitro Diagnostic Products, andTherapeutic Products (CBER and CDER)Therapeutic Products (CBER and CDER)
Domestic and Foreign EstablishmentsDomestic and Foreign Establishments
8/9/2019 Lyophilization Processes Jan 05
8/42
TEAM BIOLOGICSTEAM BIOLOGICS -- ComplianceCompliance
SPECIALIZED GROUP OF ORA COMPLIANCE OFFICERSSPECIALIZED GROUP OF ORA COMPLIANCE OFFICERSTHAT REPORT TO ORAS OFFICE OF ENFORCEMENTTHAT REPORT TO ORAS OFFICE OF ENFORCEMENT
REVIEW AND EVALUATE INSPECTIONS PERFORMED BYREVIEW AND EVALUATE INSPECTIONS PERFORMED BYTEAM BIOLOGICS INVESTIGATORSTEAM BIOLOGICS INVESTIGATORS
WORK CLOSELY WITH CBER AND CDER COMPLIANCEWORK CLOSELY WITH CBER AND CDER COMPLIANCE
SUBJECT TO OCC REVIEW PROCEDURESSUBJECT TO OCC REVIEW PROCEDURES
8/9/2019 Lyophilization Processes Jan 05
9/42
CENTER COMPLIANCECENTER COMPLIANCE
CBER OFFICE OFCBER OFFICE OFCOMPLIANCE ANDCOMPLIANCE ANDBIOLOGICS QUALITYBIOLOGICS QUALITY
CDER OFFICE OFCDER OFFICE OFCOMPLIANCECOMPLIANCE
8/9/2019 Lyophilization Processes Jan 05
10/42
REGULATORY OPTIONSREGULATORY OPTIONS
ADVISORY ACTIONSADVISORY ACTIONS
UNTITLED LETTERSUNTITLED LETTERS
The agency has a need to communicate withThe agency has a need to communicate withregulated industry about documentedregulated industry about documented
violations that do not meet the threshold ofviolations that do not meet the threshold ofregulatory significanceregulatory significance
8/9/2019 Lyophilization Processes Jan 05
11/42
REGULATORY OPTIONSREGULATORY OPTIONS
ADVISORY ACTIONS (contd):ADVISORY ACTIONS (contd):
WARNING LETTERSWARNING LETTERS
A Warning Letter is a written communication from FDAA Warning Letter is a written communication from FDAnotifying an individual or firm that the agency considersnotifying an individual or firm that the agency considersone or more products, practices, processes, or otherone or more products, practices, processes, or otheractivities to be in violation of the Federal FD&C Act, oractivities to be in violation of the Federal FD&C Act, orother acts, and that failure of the responsible party toother acts, and that failure of the responsible party to
take appropriate and prompt action to correct andtake appropriate and prompt action to correct andprevent any future repeat of the violation, may result inprevent any future repeat of the violation, may result inadministrative and/or regulatory enforcement actionadministrative and/or regulatory enforcement actionwithout further notice.without further notice.
8/9/2019 Lyophilization Processes Jan 05
12/42
8/9/2019 Lyophilization Processes Jan 05
13/42
8/9/2019 Lyophilization Processes Jan 05
14/42
ENFORCEMENT POSTUREENFORCEMENT POSTURE
CONSUMER ACCESS TO SAFE ANDCONSUMER ACCESS TO SAFE AND
EFFECTIVE PRODUCTSEFFECTIVE PRODUCTS
VOLUNTARY CORRECTIONVOLUNTARY CORRECTION
8/9/2019 Lyophilization Processes Jan 05
15/42
ENFORCEMENT POSTUREENFORCEMENT POSTURE
PRODUCTSPRODUCTS SCOPE AND IMPACTSCOPE AND IMPACT
PRIOR HISTORYPRIOR HISTORY VERY IMPORTANTVERY IMPORTANT PREVIOUS INSPECTIONAL FINDINGSPREVIOUS INSPECTIONAL FINDINGS
RESPONSESRESPONSES
EFFECTIVENESS OF CORRECTIVE ACTIONS ANDEFFECTIVENESS OF CORRECTIVE ACTIONS ANDPREVENTATIVE MEASURESPREVENTATIVE MEASURES
ADVISORY AND ENFORCEMENT ACTIONSADVISORY AND ENFORCEMENT ACTIONS
8/9/2019 Lyophilization Processes Jan 05
16/42
ENFORCEMENT POSTUREENFORCEMENT POSTURE
IMPORT ACTIVITIESIMPORT ACTIVITIES
ALERTSALERTS
DETENTION OF PRODUCTDETENTION OF PRODUCT
REFUSAL OF ENTRYREFUSAL OF ENTRY
8/9/2019 Lyophilization Processes Jan 05
17/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
a temperature distribution study toa temperature distribution study to
assure that all shelves of the lyophilizersassure that all shelves of the lyophilizersobtain and maintain a temperature ofobtain and maintain a temperature of --40C during freeze drying operations has40C during freeze drying operations hasnot been performednot been performed
8/9/2019 Lyophilization Processes Jan 05
18/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
The lyophilization cycle for the vialThe lyophilization cycle for the vialconfiguration has not been validated.configuration has not been validated.
8/9/2019 Lyophilization Processes Jan 05
19/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
Failure to notify FDAofchanges inFailure to notify FDAofchanges in
equipment and the product process forequipment and the product process foryour productin that:a sixyour productin that:a sixshelflyophilizer was installed and is beingshelflyophilizer was installed and is beingutilized in the freeze drying of yourutilized in the freeze drying of your
product.product.
8/9/2019 Lyophilization Processes Jan 05
20/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
lyophilizerdid not achieve the specifiedlyophilizerdid not achieve the specified
pressure during primary dryingPartiallypressure during primary dryingPartiallystoppered product vials were storedforstoppered product vials were storedfor62 hours inside lyophilizerno62 hours inside lyophilizernodocumentation that the impactwasdocumentation that the impactwas
evaluatedevaluated
8/9/2019 Lyophilization Processes Jan 05
21/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
the lyophilization cyclethe lyophilization cycle currentlycurrently ininusehas not been validatedusehas not been validated
8/9/2019 Lyophilization Processes Jan 05
22/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
process validation was performed using
process validation was performed usingdata from eight lyophilization runs. Threedata from eight lyophilization runs. Three
lots were rejected, and one lot was notlots were rejected, and one lot was notreleasedreleased
8/9/2019 Lyophilization Processes Jan 05
23/42
VIOLATION EXAMPLESVIOLATION EXAMPLES
Failure to validate processes which can notFailure to validate processes which can notbe verified by subsequent inspection inbe verified by subsequent inspection inthat the lyophilization process has notthat the lyophilization process has notbeen validated.been validated.
8/9/2019 Lyophilization Processes Jan 05
24/42
RESPONSESRESPONSES
1.1. Clear understanding of the deviation/violationClear understanding of the deviation/violation
2.2. If you dont agree, then say so. Explain yourIf you dont agree, then say so. Explain your
reasoningreasoning
How and when???How and when???
-- During the inspection,During the inspection,
-- At the closeout,At the closeout,
-- In your written response.In your written response.
8/9/2019 Lyophilization Processes Jan 05
25/42
RESPONSESRESPONSES
An evaluation of the deviation/violation thatAn evaluation of the deviation/violation thatincludes:includes:
-- the specific incident(s) citedthe specific incident(s) cited
-- impact on product(s) or process(es)impact on product(s) or process(es)
-- specific corrective actions for thatspecific corrective actions for thatincidentincident
8/9/2019 Lyophilization Processes Jan 05
26/42
RESPONSESRESPONSES
-- possibility of other affected lots, products,possibility of other affected lots, products,
processes, manufacturing locationsprocesses, manufacturing locations
-- affected marketed lots/productsaffected marketed lots/products
-- global corrective actions, employeeglobal corrective actions, employeetraining, SOP revisions, etc.training, SOP revisions, etc.
8/9/2019 Lyophilization Processes Jan 05
27/42
Dispute ResolutionDispute Resolution
Policies and procedures that would allowPolicies and procedures that would allow
rapidrapid,, objectiveobjective resolution ofresolution ofscientificscientificandand technicaltechnicalquestions and issues thatquestions and issues thatmay arise either during an inspection or asmay arise either during an inspection or asthe result of an inspection.the result of an inspection.
8/9/2019 Lyophilization Processes Jan 05
28/42
8/9/2019 Lyophilization Processes Jan 05
29/42
WHO MAY DISPUTE?WHO MAY DISPUTE?
The Manufacturer or Establishment thatThe Manufacturer or Establishment thatwas inspected.was inspected.
Domestic or International EntityDomestic or International Entity
Human and Veterinary DrugsHuman and Veterinary Drugs
Human Biological DrugsHuman Biological Drugs
8/9/2019 Lyophilization Processes Jan 05
30/42
WHY WOULD YOU DISPUTE?WHY WOULD YOU DISPUTE?
A SATISFACTORY RESOLUTION COULDA SATISFACTORY RESOLUTION COULDNOT BE OBTAINED DURING THENOT BE OBTAINED DURING THEINSPECTION(complexity, etc)INSPECTION(complexity, etc)
-- ANDAND --
THE FDATHE FDA--483 HAS BEEN ISSUED483 HAS BEEN ISSUED
8/9/2019 Lyophilization Processes Jan 05
31/42
What May Be Disputed?What May Be Disputed?
A Scientific or Technical Issue related toA Scientific or Technical Issue related toGood Manufacturing PracticesGood Manufacturing Practices AdequacyAdequacy
AppropriatenessAppropriateness InterpretationInterpretation
A Scientific or Technical Issue RaisedA Scientific or Technical Issue Raised
During an InspectionDuring an InspectionGMP [CBER/CDER/CVM] orGMP [CBER/CDER/CVM] or
PAIPAI [CDER/CVM][CDER/CVM]
8/9/2019 Lyophilization Processes Jan 05
32/42
What May Not Be Disputed?What May Not Be Disputed?
Precise Requirements of the regulationsPrecise Requirements of the regulationsor in an Approved Applicationor in an Approved Application
Issues Not Raised During An InspectionIssues Not Raised During An Inspection
Procedural or Administrative IssuesProcedural or Administrative Issues
Writing style/wording differencesWriting style/wording differences
8/9/2019 Lyophilization Processes Jan 05
33/42
WHEN CAN YOU DISPUTE?WHEN CAN YOU DISPUTE?
DURING THE INSPECTION, FDADURING THE INSPECTION, FDA
STRONGLY ENCOURAGES OPENSTRONGLY ENCOURAGES OPENDIALOGUE ON ALL ISSUES BY AND WITHDIALOGUE ON ALL ISSUES BY AND WITHTHE INSPECTION TEAM IN HOPES TOTHE INSPECTION TEAM IN HOPES TOHAVE ALL ISSUES UNDERSTOOD ANDHAVE ALL ISSUES UNDERSTOOD AND
RESOLVED, IN THE MOST EFFICIENTRESOLVED, IN THE MOST EFFICIENTMANNER.MANNER.
8/9/2019 Lyophilization Processes Jan 05
34/42
WHEN?WHEN?
TIERTIER--1: WITHIN 10 BUSINESS DAYS OF1: WITHIN 10 BUSINESS DAYS OFTHE ISSUANCE OF THE 483THE ISSUANCE OF THE 483
TIERTIER--2: WITHIN 60 DAYS OF RECEIPT2: WITHIN 60 DAYS OF RECEIPTOF THE TIEROF THE TIER--1 DECISION1 DECISION
Failure to adhere to these time frames couldFailure to adhere to these time frames couldresultinarefusalto considerresultinarefusalto consider
8/9/2019 Lyophilization Processes Jan 05
35/42
TIERTIER--1: Initial Request For Resolution1: Initial Request For Resolution
1.1. Nature of dispute in written formatNature of dispute in written format
2.2. Include supporting documentationInclude supporting documentation **
*This should not include any information that was not*This should not include any information that was notpresented to the Inspection Team during thepresented to the Inspection Team during theinspection.inspection.
8/9/2019 Lyophilization Processes Jan 05
36/42
TIERTIER--1 Process1 Process
ORA Review and EvaluationORA Review and Evaluation
Written response within 30 days:Written response within 30 days:
We agree with youWe agree with you
We disagree with youWe disagree with youYou request does not qualify orYou request does not qualify or
additional review time is neededadditional review time is needed
8/9/2019 Lyophilization Processes Jan 05
37/42
TIERTIER--22 APPEAL INITIAL DECISIONAPPEAL INITIAL DECISION
1.1. Must be in written formatMust be in written format
2.2. Request resolution by D.R. PanelRequest resolution by D.R. Panel
3.3. Nature of continuing disputeNature of continuing dispute
4.4. Include supporting documentsInclude supporting documents
8/9/2019 Lyophilization Processes Jan 05
38/42
TIERTIER--2 Process2 Process
Dispute Resolution PanelDispute Resolution Panel
Panel Membership (integrated and neutralPanel Membership (integrated and neutral nonopreviously involved decision makers)previously involved decision makers)
Decide to accept, review, and evaluateDecide to accept, review, and evaluate
Dispute is reviewed during Panel MeetingsDispute is reviewed during Panel Meetings
8/9/2019 Lyophilization Processes Jan 05
39/42
TIERTIER--2 Process2 Process
D.R. Panel Review and EvaluationD.R. Panel Review and Evaluation
Written response within 30 days:Written response within 30 days:
We agree with youWe agree with you
We disagree with youWe disagree with youYou request does not qualify orYou request does not qualify or
additional review time is neededadditional review time is needed
8/9/2019 Lyophilization Processes Jan 05
40/42
FINAL DECISIONSFINAL DECISIONS
TIERTIER--1 and TIER1 and TIER--22
The Program Center is notified and makesThe Program Center is notified and makesdecision available for public dissemination,decision available for public dissemination,to promote consistency of application andto promote consistency of application andinterpretation.interpretation.
8/9/2019 Lyophilization Processes Jan 05
41/42
8/9/2019 Lyophilization Processes Jan 05
42/42
ReferencesReferences
Warning Letters are posted at:Warning Letters are posted at: www.fda.govwww.fda.gov
Inspectional Guidances:Inspectional Guidances:
www.fda.gov/ora/inspect_refwww.fda.gov/ora/inspect_ref
Title 21 Code of Federal Regulations (CFR)Title 21 Code of Federal Regulations (CFR)
Draft Dispute Resolution Procedures:Draft Dispute Resolution Procedures:www.fda.gov/cder/guidance/5804dft.htmwww.fda.gov/cder/guidance/5804dft.htm